The non-receptor tyrosine kinase inhibitors market plays a crucial role in the treatment of various diseases, with oncology being the primary therapeutic area. Globally, cancer remains a leading cause of mortality, with 19.3 million new cases and 10 million deaths in 2020 (GLOBOCAN). Non-receptor tyrosine kinase inhibitors, such as those targeting ALK, BCR-ABL, or JAK pathways, are widely used in hematological malignancies such as chronic myeloid leukemia (CML) and lymphomas. For instance, Chronic Myeloid Leukemia (CML), approximately 1.2 million people live with leukemia worldwide, with non-receptor inhibitors such as Imatinib revolutionizing treatment.
